- Home
- MMD vs NVCT Comparison
MMD vs NVCT Comparison
Compare MMD & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMD | NVCT |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.8M | 274.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MMD | NVCT |
|---|---|---|
| Price | $15.45 | $26.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 43.6K | ★ 201.9K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $5.55 |
| 52 Week High | $15.82 | $27.93 |
Technical Indicators
Market Signals| Indicator | MMD | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 90.33 |
| Support Level | $14.94 | $6.74 |
| Resistance Level | $15.81 | N/A |
| Average True Range (ATR) | 0.19 | 2.09 |
| MACD | 0.01 | 1.85 |
| Stochastic Oscillator | 81.13 | 93.56 |
Price Performance
Historical ComparisonAbout MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.